AgomAb Therapeutics NV
AGMB- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0002020932
No open-market purchases or sales by AgomAb Therapeutics NV insiders were filed in the last 90 days; 34 institutions reported holding it in 13F filings for Q2 2026, worth $357.3M in total; no superinvestor holds it.
13F holders, Q2 2026
Institutional positions in AgomAb Therapeutics NV as of Jun 30, 2026. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 34
- +2 vs. Q1 2026
- Shares held
- 27.5M
- +4.17M (+17.9%) vs. Q1 2026
- Total value
- $357.3M
- +$112.0M (+45.7%) vs. Q1 2026
- New holders
- 9
- 4 more added
- Sold out
- 7
- 6 more reduced
Compare with Q1 2026: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting AGMB on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 34 | $357.3M |
| Q1 2026 | 32 | $245.3M |
| Q4 2025 | 0 | $0 |
| Q3 2025 | 0 | $0 |
| Q2 2025 | 0 | $0 |
| Q1 2025 | 0 | $0 |
| Q4 2024 | 0 | $0 |
| Q3 2024 | 0 | $0 |
| Q2 2024 | 0 | $0 |
| Q1 2024 | 0 | $0 |
| Q4 2023 | 0 | $0 |
| Q3 2023 | 0 | $0 |
| Q2 2023 | 0 | $0 |
| Q1 2023 | 0 | $0 |
| Q4 2022 | 0 | $0 |
| Q3 2022 | 0 | $0 |
| Q2 2022 | 0 | $0 |
| Q1 2022 | 0 | $0 |
| Q4 2021 | 0 | $0 |
| Q3 2021 | 0 | $0 |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q2 2026
Shares, value and share of portfolio for each institution holding AgomAb Therapeutics NV; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| EQT Fund Management S.a r.l. | 5,141,992 | $66.7M | 7.74% | 00.0% | Unchanged |
| Nantahala Capital Management, LLC | 3,136,376 | $40.7M | 1.23% | +1,936,376+161.4% | Added |
| Sanofi | 2,783,096 | $36.1M | 6.76% | 00.0% | Unchanged |
| Redmile Group, LLC | 2,733,926 | $35.5M | 2.38% | +2,577,676+1,649.7% | Added |
| Cormorant Asset Management, LP | 2,465,348 | $32.0M | 1.64% | 00.0% | Unchanged |
| TCG Crossover Management, LLC | 2,053,233 | $26.7M | 0.64% | 00.0% | Unchanged |
| Federated Hermes, Inc. | 1,618,000 | $21.0M | 0.03% | 00.0% | Unchanged |
| Casdin Capital, LLC | 1,550,000 | $20.1M | 1.01% | 00.0% | Unchanged |
| Andera Partners | 1,538,702 | $20.0M | 9.67% | 00.0% | Unchanged |
| FMR LLC | 1,458,677 | $18.9M | 0.00% | 00.0% | Unchanged |
| Standard Life Aberdeen plc | 846,695 | $11.0M | 0.02% | +139,039+19.6% | Added |
| Perceptive Advisors LLC | 600,000 | $7.79M | 0.12% | 00.0% | Unchanged |
| Samsara BioCapital, LLC | 600,000 | $7.79M | 0.64% | 00.0% | Unchanged |
| Siren, L.L.C. | 411,250 | $5.34M | 0.11% | 00.0% | Unchanged |
| OrbiMed Advisors LLC | 192,740 | $2.50M | 0.05% | +192,740 | New |
| Pfizer Inc | 75,000 | $1.04M | 0.61% | 00.0% | Unchanged |
| Alps Advisors Inc | 49,984 | $648.8K | 0.00% | +49,984 | New |
| Bellevue Group AG | 49,248 | $639.2K | 0.01% | −752−1.5% | Reduced |
| Seven Grand Managers, LLC | 47,600 | $617.8K | 0.02% | −152,400−76.2% | Reduced |
| Sectoral Asset Management Inc | 43,500 | $564.6K | 0.39% | 00.0% | Unchanged |
| Burkehill Global Management, LP | 35,000 | $454.3K | 0.02% | 00.0% | Unchanged |
| Quadrature Capital Ltd | 20,461 | $265.6K | 0.00% | +20,461 | New |
| Two Sigma Investments, LP | 18,072 | $234.6K | 0.00% | +3,831+26.9% | Added |
| HRT Financial LP | 17,075 | $221.0K | 0.00% | −6,651−28.0% | Reduced |
| Goldman Sachs Group Inc | 11,800 | $153.2K | 0.00% | −23,939−67.0% | Reduced |
| XTX Topco Ltd | 10,271 | $133.3K | 0.00% | +10,271 | New |
| Citigroup Inc | 9,496 | $123.3K | 0.00% | +9,496 | New |
| UBS Group AG | 2,128 | $27.6K | 0.00% | −4,309−66.9% | Reduced |
| GAMMA Investing LLC | 1,344 | $17.4K | 0.00% | +1,344 | New |
| Morgan Stanley | 1,200 | $15.6K | 0.00% | −1,825−60.3% | Reduced |
| BNP Paribas Arbitrage, SA | 754 | $9.79K | 0.00% | +754 | New |
| Larson Financial Group LLC | 698 | $9.06K | 0.00% | +698 | New |
| SBI Securities Co., Ltd. | 2 | $26 | 0.00% | 00.0% | Unchanged |
| Caitong International Asset Management Co., Ltd | 2 | $26 | 0.00% | +2 | New |
| LMR Partners LLP | 0 | $0 | 0.00% | −300,000−100.0% | Sold out |
| Millennium Management LLC | 0 | $0 | 0.00% | −95,233−100.0% | Sold out |
| Alyeska Investment Group, L.P. | 0 | $0 | 0.00% | −75,000−100.0% | Sold out |
| Laurion Capital Management LP | 0 | $0 | 0.00% | −50,000−100.0% | Sold out |
| Citadel Advisors LLC | 0 | $0 | 0.00% | −35,000−100.0% | Sold out |
| D. E. Shaw & Co., Inc. | 0 | $0 | 0.00% | −15,326−100.0% | Sold out |
| Jane Street Group, LLC | 0 | $0 | 0.00% | −12,794−100.0% | Sold out |